NeuClone says it is on track to be “among the first biosimilar entrants” to challenge Janssen’s Stelara (ustekinumab) after its NeuLara biosimilar candidate produced positive Phase I trial results.
“NeuLara has successfully met all primary and secondary endpoints in a Phase I clinical trial,” the firm announced. “This includes...






